Announcement on Change of Sponsor Representative
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Change of Sponsor Representative
Filed with SSE ·
6ix hasn’t read this filing yet.
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Expected Increase in Performance for 2025
- Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Glargine Injection and Its Pre-filled Injection Pen
- Announcement on Obtaining of European Commission Marketing Authorization for Insulin Glargine Injection
- Announcement on Progress in Redemption of Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
- Announcement on the Dismissal of Senior Management Member and Designation of Designated Personnel to Assume the Duties of the Financial Director
Later from Gan & Lee Pharmaceuticals
- Announcement on Positive Opinion from the European Medicines Agency's CHMP on the Marketing Authorization Application for Insulin Lispro Injection (Bysumlog®) and Insulin Aspart Injection (Dazparda®)
- Announcement on Appointment of Senior Management Members
- Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
- Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
- Announcement on the Company Passing ANVISA GMP Certification
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals